BioMarker Strategies Announces Chinese Patent for PathMAP Functional Signaling Profile Technology

Published: Jun 04, 2018

“Compositions and Methods for Prediction of Drug Sensitivity, Resistance, and Disease Progression” (Chinese Patent #ZL 201180030332.9) - Exclusivity until April 2031
 

ROCKVILLE, Md.--(BUSINESS WIRE)-- BioMarker Strategies, LLC, today announced that the Chinese Patent Office has granted a patent covering the Company’s PathMAP® Functional Signaling Profile technology. The announcement was made today at the BIO International Convention, which is back in Boston, Massachusetts to celebrate history-making innovation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180604005351/en/

The SnapPath® Cancer Diagnostics System is the only diagnostics system that can generate purified po ...

The SnapPath® Cancer Diagnostics System is the only diagnostics system that can generate purified populations of live solid tumor cells from live, unfixed samples in an automated and standardized manner. SnapPath preserves the molecular integrity of these living cells for exposure outside the human body to targeted therapies. This enables the generation of PathMap® Functional Signaling Profiles, which are highly predictive of individual solid tumor response to targeted therapies, because they are based on the dynamic, predictive signaling information available only from live cells. BioMarker Strategies today announced that the Chinese Patent Office has granted a patent covering its PathMAP technology. Patents have previously been granted on both of these important technologies in the United States, Europe, Australia, Canada and Japan. (Photo: Business Wire)

“PathMAP Functional Signaling Profiles are made possible by our proprietary SnapPath Cancer Diagnostics System, which was developed specifically to enable predictive tests to guide targeted drug development and treatment selection for patients with solid tumor cancers,” said Jerry Parrott, President and CEO, BioMarker Strategies. “PathMAP Profiles are highly predictive of individual solid tumor responses to targeted therapies and combinations because they are based on the dynamic, predictive signaling information available only from live cells.”

The SnapPath and PathMAP technologies are ideally suited to assess response to targeted drugs in development for treatment of solid tumor cancers. The BioMarker Strategies business model is focused on using its proprietary ex vivo technology to provide research services to companies developing targeted drugs and combinations for the treatment of patients with these cancers.

“Our Company was founded to address the reality that available biomarker tests for solid tumors primarily rely on dead, fixed tissue samples,” Mr. Parrott said. “Tests based on such static samples can identify mutations and suggest general therapeutic approach, but are not generally useful in identifying or understanding mechanisms of acquired resistance, and do not accurately and dependably predict individual tumor response to treatment.”

 

Patents Granted BioMarker Strategies for the SnapPath® Cancer Diagnostics System:

“Improved Methods and Devices for Cellular Analysis”

Country/Region

 

Patent #

 

Issue Date

 

Expiration

United States   US9121801   September 1, 2015   December 28, 2030
Europe   EP2210080   January 28, 2015   October 24, 2028
Australia   AU2008317329   January 15, 2015   October 24, 2028
Australia   AU2014277688   January 19, 2017   October 24, 2028
Canada   CA2703631   August 22, 2017   October 24, 2028
Hong Kong   HK1145878   August 14, 2015   October 24, 2028
Japan   JP6177841   July 21, 2017   October 24, 2028
Korea   KR10-1658245   September 9, 2016   October 24, 2028
 
 

Patents Granted for the Company’s PathMAP® Functional Signaling Profile Technology:

“Compositions for Prediction of Drug Sensitivity, Resistance and Disease Progression”

Country/Region

 

Patent #

 

Issue Date

 

Expiration

United States   US9766249   September 19, 2017   August 31, 2025
Europe   EP2561368   August 2, 2017   April 18, 2031
Australia   AU2011242990   May 28, 2015   April 18, 2031
Canada   CA2795362   March 20, 2018   April 18, 2031
China   ZL201180030332.9   April 13, 2018   April 18, 2031
Japan   JP6158078   June 16, 2017   April 18, 2031
Singapore   SG184507   May 6, 2015   April 18, 2031
 

About BioMarker Strategies

BioMarker Strategies developed the SnapPath Cancer Diagnostics System. SnapPath is an automated and highly customizable fluidics-based system consisting of a compact bench-top instrument and a single-use cartridge for required consumables and reagents. The SnapPath System generates purified populations of live solid tumor cells from fresh biopsies or other fresh tissue samples such as xenografts or tumorgrafts, and keeps them alive on the instrument to enable generation of the highly predictive PathMAP Functional Signaling Profiles.

The capabilities of SnapPath and the Functional Signaling Profiles it enables are available for use in preclinical studies in tumorgraft and other model systems, and in early clinical studies to assess pharmacodynamic changes in the solid tumors of individual patients. For more information about BioMarker Strategies, please see www.biomarkerstrategies.com.

Forward-Looking Statements

The information in this press release includes our projections and other forward-looking statements regarding future events. In some cases, forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “projects,” “estimates,” “predicts,” “potential,” “continue”, etc. These statements are not guarantees of future performance or achievement and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is projected here.

 

Contacts

BioMarker Strategies, LLC
Jerry Parrott, President & CEO
301-938-4043 Mobile
jparrott@biomarkerstrategies.com

Source: BioMarker Strategies, LLC

 

 

Back to news